Investment
Features
FeesSafety
Academy
More
Pluang+

Opaleye Management sells $7.8M in Harrow shares but keeps a 10% stake, signaling tactical profit-taking.

Market News
24 Mar 2026
Andy Gould
View Source
Neutral
pluang ai news

Opaleye Management Inc. sold 198,572 shares of Harrow stock worth about $7.8 million over two days in early March 2026, shortly after Harrow reported weaker-than-expected Q4 earnings. Despite the sale, Opaleye retains an indirect position of approximately 3.68 million shares, representing nearly 10% ownership in Harrow. This sale appears to be a strategic profit-taking move following a strong stock run rather than a loss of confidence, as Opaleye remains a major institutional backer of the company. Investors should view this as a portfolio adjustment rather than a signal of fundamental change.

More News

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...

Market News
Bullish
3 hours ago
QuickLogic and PQSecure demo post-quantum cryptography on reprogrammable eFPGA for future-proof security.

QuickLogic and PQSecure demo post-quantum cryptography on reprogrammable eFPGA for future-proof security.

QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...

Market News
Bullish
4 hours ago
Relmada Therapeutics to report Q2 2026 financial results on August 6, 2026

Relmada Therapeutics to report Q2 2026 financial results on August 6, 2026

Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...

Company Fundamentals
Neutral
4 hours ago
Gilat Satellite Networks to report Q2 2026 results on August 5 with CEO and CFO call.

Gilat Satellite Networks to report Q2 2026 results on August 5 with CEO and CFO call.

Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...

Company Fundamentals
Neutral
4 hours ago
B&M's Q1 update splits analysts as Deutsche Bank upgrades but Panmure Liberum downgrades on growth doubts

B&M's Q1 update splits analysts as Deutsche Bank upgrades but Panmure Liberum downgrades on growth doubts

B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...

Analyst Insights
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App